Abstract
Purpose :
To report visual and outcomes, survival rate and short-term complications in patients treated with primary Boston Keratoprosthesis Type I Lucia Design
Methods :
This is a retrospective chart review of patients that underwent Lucia Keratoprosthesis as Primary Penetrating Procedure(KPPP)(FIG 1). Suitable patients for KPPP were those who weren't candidates for conventional PKP, including severe bilateral limbal stem cell disease, ocular surface chemical burns or immune mediated ocular surface disease. Analyzed variables include diagnosis prior to transplantation, age, gender, BCVA, IOP, and postop complications. Chisquare test was used to analyze categorical data. Preop and postop LogMAR VA were compared by paired two-tailed t-test.. Log-rank test was performed on Kaplan-Meier survival curves for maintenance of VA and device retention.
Results :
From 30 eyes that underwent Lucia keratoprotheses procedure. 9 patients were included as recimpient of Lucia KPPP . Mean age 49.25 ±19.25 yo. Average follow up 10 ± 3.25 months. Mean preop VA 2.40±0.38 logMAR, immediate postop VA was 1.14 ± 0.34 logMAR and 0.87± 0.78 logMAR at end of follow up (8 mo) having a statistically significant improvement (p<0.05). Most frequent complication was retroprothesic membrane formation in 3 eyes, ocular hypertension in 1 eye, retinal detachment in 1 eye andVitreous hemorrhage in 1 eye. Five eyes (55%) had prior diagnosis of glaucoma. Device retention throughout the follow-up period was 100%.
Conclusions :
Our study is the First short-term study reporting Lucia KPPP outcomes, it may be a safe and effective procedure for certain indications where a PK would be expected to fail.The reported incidence of postoperative IOP elevation suggest a longer follow-up to determine if CDVA is maintained.Lucia KPPP provides a significantly CDVA ≥20/200 at least on the short term. Results are comparable with type I Boston KPPP with the undoubtable advantage of reaching a higher quantity of patients because of its costs, especially in our population.
This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.